UNSPSC 51171906: Lansoprazole

This classification denotes a proton pump inhibitor with the molecular formula C16H14F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0K5C5T2QPG, chemically known as 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole but generally known as lansoprazole, which bears US NIH Compound Identifier 3883. European Medicines Agency schedules Lansoprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08403MIG.

UNSPSC 51171906 Lansoprazole, a Commodity code, shows limited recent state and local procurement activity directly aligned with the pharmaceutical product itself. The three recent opportunities tagged to this code span offender drug testing services, direct-to-manufacturer prescription program planning, and generic multi-source pharmaceutical contracting — none of which center on lansoprazole as a line-item procurement. The mismatch suggests that state and local buyers are not currently soliciting lansoprazole as a standalone pharmaceutical commodity through conventional procurement channels; instead, the code appears to capture pharmaceutical purchasing within broader service contracts (testing, benefit management, and cooperative purchasing vehicles) where individual drug products are secondary to contract scope or are procured through established wholesaler relationships and GPO arrangements rather than direct manufacturer or distributor solicitations.

The geographic spread of recent activity includes Texas, Minnesota, and Oregon, reflecting activity through state health agencies and cooperative purchasing alliances rather than concentrated demand from a single jurisdiction. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, with an estimated contract value of $600,000), the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and OTC products under RFP S1070000015802 (proposals due March 26, 2026). None of these solicitations explicitly target lansoprazole or other specific pharmaceuticals as primary commodities; instead, they address pharmaceutical acquisition through service delivery, benefit management restructuring, or group purchasing agreements where individual products flow through authorized wholesalers and established supply chains. A firm pursuing lansoprazole sales to state and local buyers would be better served by tracking pharmaceutical distributor and GPO contracts rather than competing directly under this commodity code.